GEN Exclusives

More »

GEN News Highlights

More »
Jun 18, 2008

Merck Partners with Nuevolution for Access to Chemetics Platform

  • Merck inked a drug discovery collaboration with Nuevolution to gain access to its  Chemetics® drug discovery technology. The firms will collaborate to identify small molecule leads against several drug targets of interest to Merck. Chemetics uses DNA labeling to allow fragment-based drug screening.

    Nuevolution will screen multiple multi-million member diverse fragment based screening libraries for hit identification. Through the design, synthesis, and screening of target-focused Chemetics follow-up libraries, the parties will also work together to perform hit-to-lead optimization.

    Merck will fund the research with an upfront payment to Nuevolution and will make milestone payments as candidate molecules progress through preclinical and clinical development and onto the market. Additionally, Nuevolution is eligible to receive royalties on the commercial sales of approved products.

    Related Links:

    Nuevolution Announces Drug Discovery Alliance With Lexicon Pharmaceuticals

    Fragment-Based Approach Increases Leads



Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...
More »

GEN Poll

More » Poll Results »

Should the CDC Director Resign?

Do you think the CDC chief should resign?